MENU

GLYC Stock GlycoMimetics (GLYC, $0.25) Moving Average Convergence Divergence (MACD) Histogram turned positive on December 30, 2024

A.I.dvisor
at Tickeron.com
Loading...
GLYC - GlycoMimetics
MACD signal
Bullish Trend
Odds of UP Trend
Tickeron
MACD signal
Price: $0.2487
Daily change: +$0.0123 (+5.2%)
Daily volume: 960.1K
Capitalization: $16M
Industry: Biotechnology
This is a Bullish indicator signaling GLYC's price could rise from here. Traders may explore going long the stock or buying call options. A.I. dvisor identified 47 similar cases where GLYC's MACD histogram became positive, and of them led to successful outcomes. Odds of Success:

GLYC's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for GLYC turned positive on December 30, 2024. Looking at past instances where GLYC's MACD turned positive, the stock continued to rise in of 46 cases over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where GLYC's RSI Indicator exited the oversold zone, of 38 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on December 30, 2024. You may want to consider a long position or call options on GLYC as a result. In of 97 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where GLYC advanced for three days, in of 237 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where GLYC declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

GLYC broke above its upper Bollinger Band on January 03, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for GLYC entered a downward trend on December 31, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. GLYC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.475) is normal, around the industry mean (14.746). P/E Ratio (0.000) is within average values for comparable stocks, (88.252). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.853). GLYC has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.013). GLYC's P/S Ratio (1666.667) is slightly higher than the industry average of (264.084).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GLYC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
GLYC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of drugs to treat inflammatory diseases and cancer

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
9708 Medical Center Drive
Phone
+1 240 243-1201
Employees
35
Web
https://www.glycomimetics.com